Search

314 Result(s)
Sort by

Agreement-to-acquire-NBE-Therapeutics

Agreement-to-acquire-NBE-Therapeutics

Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Vaccine bluetongue virus serotype 3 sheep cattle

Vaccine bluetongue virus serotype 3 sheep cattle

BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
Revolutionizing drug development

Revolutionizing drug development

Our scientists are leveraging the "digital twins"-technology to revolutionize biotherapeutic drug development.
Oliver Sluke

Oliver Sluke

Oliver Sluke on global business with a world of perspectives
Data Science

Data Science

Revolutionizing research and development with data driven insights